1. Closer to the Source: Targeted-Release Corticosteroids for Immunoglobulin A Nephropathy 
Heather N. Reich 
American Journal of Kidney Diseases 
Volume 71, Issue 1, Pages 6-8 (January 2018)
DOI: /j.ajkd
Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
NEFIGAN Study design. Following a 6-month run-in phase to optimize conservative therapy, eligible patients were randomly assigned to 1 of 3 treatment groups. Two doses of targeted-release-formulation budesonide (Nefecon) were compared to placebo. Treatment was administered for 9 months, and participants were subsequently followed up through a 3-month taper and follow-up period. The primary outcome was percent reduction in urinary protein-creatinine ratio (UPCR) at the end of 9 months of treatment (UPCRm9) compared to randomization (UPCRm0).
American Journal of Kidney Diseases  , 6-8DOI: ( /j.ajkd )
Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions